Arechar Healthcare, one of the foremost manufacturers of the world, announced the launch of Bortecine (Bortezomib injection 2 mg), an anticancer drug used in the treatment of Multiple Myeloma and Mantle-Cell Lymphoma. The mid-60s is the most prone age to develop Multiple Myeloma or/and Mantle-Cell Lymphoma, specifically in males. Even doctors aren’t sure about the actual and the most common causes of these diseases, therefore it becomes necessary to reduce the incidence of such diseases. Keeping this factor in mind, Arechar Healthcare took a step ahead in the oncology sector and marked its presence in this field by facilitating the treatment of multiple myeloma and mantle-cell lymphoma through this medication.
“Bortezomib is the most effective regimen to treat mantle cell lymphoma and multiple myeloma, given as an injection. I am pleased to announce the launch of Bortecine with immense hope of the highest accessibility of this drug to the patients,” said Mr. Harpreet Singh, Founder of Arechar Healthcare. “Such life-saving drugs are essential to prove the definition of humanity, for the incidence of cancer is rapidly rising.”
“Ask any of the employees of Arechar Healthcare why they work every day and you will get the same response: because serving humanity is our ultimate goal,” he added.
Bortezomib is an N-protected dipeptide. It belongs to a class of medicines called proteasome inhibitors. It was originally made at Myogenics in 1995. It was approved by the US FDA in May 2003, initially for the treatment of multiple myeloma. In October 2014, Bortezomib was approved for the treatment of mantle cell lymphoma also.
Bortecine comprises a dipeptide, Bortezomib. Bortezomib is the active ingredient of this medicine. It is a proteasome inhibitor. Available in the strength of 2mg /vial, it should be given as an injection as per the duration prescribed by the healthcare provider. This injection works by blocking or slowing down the action of proteasomes inside cells.